George Q Daley

This inventor holds 19 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Stem Cell Research. Top assignees: Children's Medical Center Corporation, Harvard College, Howard Hughes Medical Institute. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George Q Daley. Retrieved from https://idiyas.com/inventor/george-q-daley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 16)

% Patents Active = 68.4

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 267(Granted Patents)

Location History:

Weston, MA (US) (2001 - 2022)
Cambridge, MA (US) (2022 - 2024)

Company Filing History:

14 out of 1,074

Children's Medical Center Corporation

Howard Hughes Medical Institute

patents

4. 1 out of 1,429

The Brigham and Women's Hospital, Inc.

patents

5. 1 out of 318

Whitehead Institute for Biomedical Research

patents

6. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Induced Pluripotent Stem Cells

Hematopoietic Stem Cells

Gene Transfer

Diamond Blackfan Anemia

LIN28

miRNA Processing

Cancer Cell Death

Tumor Regression

Nucleic Acids Detection

Chromatin Modifying Enzymes

Somatic Cell Reprogramming

Progenitor Cell Engraftment

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12680075 - IMMUNE CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELL (2026-07-14),

2. 12146162 - Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer (2024-11-19),

3. 11980620 - Compounds and methods for treatment of Diamond Blackfan anemia (2024-05-14),

4. 11572544 - Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer (2023-02-07),

5. 11525119 - Immune cells derived from induced pluripotent stem cell (2022-12-13),

6. 11512316 - Enhanced organogenesis through manipulation of LIN28/LET-7/DIS3L2 (2022-11-29),

7. 11261430 - Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells (2022-03-01),

8. 11162073 - Methods for generating functional hematopoietic stem cells (2021-11-02),

9. 9846164 - Detection of human somatic cell reprogramming (2017-12-19),

10. 9670463 - Inhibition and enhancement of reprogramming by chromatin modifying enzymes (2017-06-06),

11. 8703413 - Detection of human somatic cell reprogramming (2014-04-22),

12. 8546382 - Methods for enhancing hematopoietic progenitor cell engraftment (2013-10-01),

13. 8283331 - Methods to regulate miRNA processing by targeting Lin-28 (2012-10-09),

14. 8101412 - Method of enhancing proliferation and/or hematopoietic differentiation of stem cells (2012-01-24),

15. 7427603 - Method of enhancing proliferation and/or hematopoietic differentiation of stem cells (2008-09-23),

Title: **Innovative Contributions of George Q Daley in Stem Cell Research**

Introduction

George Q Daley is a prominent inventor based in Weston, MA, who has significantly advanced the field of stem cell research. With an impressive portfolio of 18 patents, his work focuses on developing novel methods and treatments for various hematological conditions.

Latest Patents

Among his latest patents are groundbreaking inventions that aim to revolutionize hematopoietic stem cell (HSC) therapies. One such patent details:

1. **Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer**: This patent outlines in vitro production methods for HSCs and hematopoietic stem and progenitor cells (HSPCs). The cells exhibit long-term multilineage hematopoiesis potential upon in vivo engraftment. The derivation from pluripotent stem cell-derived hemogenic endothelial cells through non-integrative episomal vectors is a crucial innovation in the field.

2. **Compounds and methods for treatment of Diamond Blackfan anemia**: This invention pertains to strategies for treating ribosomal disorders, particularly Diamond Blackfan anemia (DBA). The focus is on methods utilizing small-molecule autophagy modulators, emphasizing drug discovery and screening for effective treatments for ribosomal disorders.

Career Highlights

Throughout his career, George Q Daley has held significant positions in various research institutions, such as the Children's Medical Center Corporation. His work has not only contributed to academic knowledge but has also had practical implications in treatment methodologies.

Collaborations

Daley has collaborated with several esteemed professionals in the field, including notable figures like Eric Lander and Michele Cargill. Their joint efforts have fostered innovative solutions and advanced the understanding of stem cell biology.

Conclusion

George Q Daley exemplifies the essence of innovation within the realm of stem cell research. His groundbreaking patents contribute to significant advancements in medical science, offering hope for improved treatment options for hematological disorders. His collaborations and career achievements reflect a profound commitment to enhancing our understanding and application of stem cell technologies.

Profile summary based on public USPTO records.